Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × capivasertib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Melanoma 1 Lymphoma 1 Estrogen Receptor Positive Breast Cancer 1

Interventions

pembrolizumab 37 Nivolumab 24 Gemcitabine 24 Paclitaxel 16 Carboplatin 14 Cyclophosphamide 12 Cisplatin 12 Ipilimumab 10 Capecitabine 10 Irinotecan 8 Docetaxel 8 Dexamethasone 8 Bevacizumab 8 130-nm albumin-bound paclitaxel 8 Rituximab 7 Albumin-Bound Paclitaxel 7 Temozolomide 6 Sorafenib 6 Pemetrexed 6 Cetuximab 6 Azacitidine 6 Ascorbic Acid 6 spartalizumab 5 lenvatinib 5 fludarabine 5 cemiplimab 5 Radiotherapy 5 ibrutinib 4 avelumab 4 atezolizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡